Medications That Can Shrink Uterine Fibroids
Yes, GnRH agonists like leuprolide (Lupron) can significantly shrink uterine fibroids, while depot medroxyprogesterone acetate (Depo-Provera) has limited evidence showing modest fibroid reduction but is not a standard treatment for this purpose.
GnRH Agonists (Leuprolide/Lupron) - The Evidence-Based Choice
GnRH agonists like leuprolide acetate are effective second-line medications that significantly reduce both fibroid volume and bleeding symptoms 1. According to the 2024 ACR guidelines, both parenteral GnRH agonists (like leuprolide) and oral GnRH antagonists (elagolix, linzagolix, relugolix) are effective at significantly reducing tumor volume and are commonly used for short courses to decrease fibroid size in preparation for surgery 1.
How Well Does Lupron Work?
The FDA label data demonstrates impressive results 2:
- Mean uterine volume decreased by 41% and myoma volume decreased by 37% at final visit
- 60% of women showed ≥25% decrease in uterine volume and 54% showed ≥25% decrease in myoma volume
- Mean fibroid diameter decreased from 5.6 cm to 4.7 cm after treatment
- 95% of women became amenorrheic during treatment
- 80% experienced decreased excessive vaginal bleeding at three months
Research confirms these findings, with one multicenter study showing mean uterine volume reduction of 45% at 24 weeks, and 77% of patients achieving >25% reduction in uterine volume 3. Another study demonstrated mean uterine volume reduction of approximately 67% with mean fibroid shrinkage of 56% 4.
Critical Limitations You Must Understand
The major caveat is that fibroid shrinkage is temporary 2:
- Menses typically return within 2 months of stopping therapy
- Mean time to return to pretreatment uterine size is 8.3 months
- Cessation of therapy leads to rapid recurrence of symptoms 1
Treatment duration is limited due to significant side effects 1:
- Hypoestrogenic effects: hot flashes, headaches, hypertension
- Loss of bone mineral density (mean decrease of 2.7% in vertebral trabecular bone density after 3 months) 2
- Treatment typically limited to 3-6 months
- Combination with low-dose estrogen/progestin can mitigate hypoestrogenic symptoms and is FDA-approved 1
When to Use GnRH Agonists
The guidelines position these as second-line medical management 1. They are most appropriate for:
- Preoperative fibroid shrinkage to facilitate surgery
- Women interested in uterus-preserving therapy
- Short-term symptom control (3-6 months maximum)
- Patients who can tolerate hypoestrogenic side effects
Depo-Provera (Medroxyprogesterone Acetate) - Limited Role
Depo-Provera is NOT mentioned in the 2024 ACR guidelines as a standard treatment for fibroids, which is telling about its limited role [1-1].
The only relevant evidence is a small 2004 pilot study of 20 women showing 5:
- Mean uterine volume reduced by 48%
- Mean fibroid volume reduced by 33%
- 70% noticed improvement in bleeding pattern
- 30% became amenorrheic
However, this is a single small pilot study from 2004 with no subsequent validation or inclusion in current guidelines. The evidence quality is far inferior to that for GnRH agonists. A 2022 study examined MPA for abnormal uterine bleeding due to ovulatory dysfunction but did not address fibroid shrinkage 6.
Other Effective Options to Consider
The guidelines also highlight progesterone receptor modulators (ulipristal acetate) as having growing evidence for reducing both bleeding and bulk symptoms 1. These can be administered intermittently and have shown efficacy comparable to GnRH agonists in randomized trials 1. However, hepatotoxicity concerns have prevented FDA approval in the United States 1.
Oral GnRH antagonists (elagolix, relugolix, linzagolix) are newer alternatives that also significantly reduce tumor volume with similar efficacy to parenteral GnRH agonists 1.
Clinical Algorithm
For fibroid shrinkage:
First-line: Consider observation if symptoms are mild, as fibroids naturally shrink at menopause 1
Second-line medical management for fibroid shrinkage:
- GnRH agonists (leuprolide) or GnRH antagonists (relugolix, elagolix) for 3-6 months maximum
- Consider add-back therapy with low-dose estrogen/progestin to mitigate bone loss
- Best used as preoperative preparation before definitive surgical treatment
Depo-Provera: Not recommended as standard therapy given lack of guideline support and limited evidence
Definitive treatment: Surgical options (myomectomy, hysterectomy) or procedural interventions (UAE, MRgFUS) for long-term control
The bottom line: Use Lupron (GnRH agonist) for temporary fibroid shrinkage, typically as a bridge to surgery. Depo-Provera lacks sufficient evidence and guideline support for this indication.